Sunshine Biopharma begins construction of mouse xenograft models for pancreatic cancer

Sunshine Biopharma, a pharmaceutical company focused on the research, development and commercialisation of drugs for the treatment of various forms of cancer, has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multi-drug resistant breast cancer.

The work is being conducted in collaboration with Sunshine Biopharma’s parent company, Advanomics Corporation, the co-recipient of $1.45 million in research grants in Canada. As previously announced, Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1.

“Conducting tests in pancreatic cancer xenograft models is the next step in our preparations for doing parallel breast cancer and pancreatic cancer clinical trials of Adva-27a,” said Dr Steve N Slilaty, Chief Executive Officer, Sunshine Biopharma. “Pancreatic cancer is an extremely aggressive form of cancer with essentially no effective treatment options available today. We are heartened by the prospects that Adva-27a could become an effective therapy for patients suffering this deadly form of cancer.”

EP News Bureau – Mumbai